Advertisement
Table 1 Baseline characteristics of patients
| All patients (n = 48) | CRT responders (n = 34, 71%) | CRT non-responders (n = 14, 29%) | P value | |
|---|---|---|---|---|
| Age (years) | 65 ± 10 | 64 ± 10 | 65 ± 11 | 0.893 |
| Male, n (%) | 30 (63%) | 18 (53%) | 12(86%) | 0.033* |
| Ischemic etiology, n (%) | 15(31%) | 8 (24%) | 7 (50%) | 0.094 |
| Heart rate (bpm) | 69 ± 12 | 68 ± 12 | 71 ± 11 | 0.489 |
| QRS duration (ms) | 160 [160; 170] | 160 [160; 170] | 160 [153; 170] | 0.649 |
| QRS & 150 ms, n (%) | 40 (83%) | 29 (85%) | 11 (79%) | 0.676 |
| LBBB morphology, n (%) | 38 (79%) | 27 (79%) | 11 (79%) | 1 |
| ACE inhibitors or AR blockers, n (%) | 46 (96%) | 33 (97%) | 13(93%) | 0.503 |
| β-blockers, n (%) | 46 (96%) | 33 (97%) | 13(93%) | 0.503 |
| Diuretics, n (%) | 28 (58%) | 16 (47%) | 12(86%) | 0.014* |
| Antialdosterone, n (%) | 18(38%) | 14(41%) | 4 (29%) | 0.412 |
| LVEF (%) | 26 ± 6 | 28 ± 5 | 23 ± 5 | 0.002* |
| LVEDV (ml) | 225 ± 85 | 209 ± 78 | 265 ± 89 | 0.037* |
| LVESV (ml) | 169 ± 68 | 152 ± 57 | 207 ± 78 | 0.009* |
| Mitral regurgitation grade lll-IV, n (%) | 10(21%) | 7(21%) | 3(21%) | 0.0767 |
| TAPSE (mm) | 21 + 4 | 21 ± 4 | 20 ± 5 | 0.78 |
| GLS (%) | − 8.9 ± 3.6 | − 9.8 ± 3.4 | − 6.5 ± 3.1 | 0.003* |
